• Global annual sales AUD$7.3 million up 49% on prior year
• Australia annual sales AUD$5.2 million up 40% on prior year
• North America annual sales AUD$2.0 million up 76% on prior year

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce continued sales growth (unaudited) of Travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (GI) tract. The company has exceeded sales projections and achieved record FY25 sales of A$7.3 million, with growth just shy of 50% on the prior year. In Australia, on the back of increased consumer engagement and a clear pharmacy visibility program, Travelan achieved annual sales of A$5.2 million, growth of 40% on the prior year. The North American business continues to produce record results with strong USA sales to Amazon and improved, more targeted communication focused on the benefits of Travelan driving more users into the brand. This, together with establishing good distribution of Travelan in Canada, resulted in North American sales of A$2 million, growth of 76% on the prior year. The company has achieved record Travelan sales in all markets and will invest to grow in North America while continuing the momentum in Australia in FY26.

FY25 global sales of Travelan exceeded projections, up 49% to AUD$7.3 million on the prior year.

In FY26, the company will invest to grow Travelan in North America while continuing the momentum in Australia.